June 15th, Kinjun Data, Japan's Kyoto University iPS Cell Research Institute recently issued a statement, stating that the phase II clinical trial of bosutinib for amyotrophic lateral sclerosis (ALS) patients, also known as 'Lou Gehrig's disease', showed that this chronic myeloid leukemia treatment drug can effectively control the progression of ALS symptoms. The phase II clinical trial started in 2022, with 26 ALS patients receiving continuous treatment for 24 weeks. The trial results showed that more than half of the patients had their symptoms controlled and did not experience the specific adverse events of ALS. However, some patients experienced adverse reactions such as diarrhea and liver dysfunction. The researchers believe that it may be necessary to adjust the usage and dosage of bosutinib and provide some supportive therapy.